Safety Reading Notes

Read safety context beside the research guide.

The DAGL-alpha source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 34959715

PubMed For Dummies Article

DAGL-alpha Evidence Review: the long-form source walk-through

Quick read
  • DAGL-alpha currently has 8 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 34959715
  • The evidence classes most visible in the row language are mechanistic or pharmacological (4), preliminary human (2), insufficient (1), and preclinical (1). PMID 24346263
  • The study-design language most visible in the row language is Animal study (4), Narrative or expert review (1), and Cellular or in vitro study (1). PMID 32829065
  • The repeated topics are endocannabinoid enzyme activity or metabolic mechanisms (3), TRP channel activity or ionotropic cannabinoid target mechanisms (1), Skin and inflammatory dermatology (1), receptor, target, metabolic, or pharmacology mechanisms (1), and other mapped categories (2), which tells the reader where to start opening PubMed and DOI links. PMID 21175579

Start with the research question

DAGL-alpha is built from 8 source-backed evidence row(s) and 6 research source(s). The current evidence classes read as mechanistic or pharmacological (4), preliminary human (2), insufficient (1), and preclinical (1), and the study-design language most often reads as Animal study (4), Narrative or expert review (1), and Cellular or in vitro study (1). PMID 34959715

The row-level question is not simply whether DAGL-alpha is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are endocannabinoid enzyme activity or metabolic mechanisms (3), TRP channel activity or ionotropic cannabinoid target mechanisms (1), Skin and inflammatory dermatology (1), receptor, target, metabolic, or pharmacology mechanisms (1), and other mapped categories (2). PMID 32829065

Human evidence 2 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 35628241

Preclinical evidence 1 row

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 30787385

Mechanistic evidence 4 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 34959715

Limits and uncertainty 1 row

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 24346263

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 32829065

Where this page has the most source density

The largest bucket surfaced for this page is endocannabinoid enzyme activity or metabolic mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is endocannabinoid enzyme activity or metabolic mechanisms, which gives readers another way to see what the literature repeatedly circles. PMID 34959715

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 32829065

Bucket chapters: what the literature is circling

endocannabinoid enzyme activity or metabolic mechanisms

2 research sources 2 rows (304-306) Preclinical research summary: insufficient (1), preclinical (1)

DAGL-alpha appears in rows about endocannabinoid enzyme activity or metabolic mechanisms mechanisms. It currently draws from 2 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 34959715

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 34959715

  • Evidence row 304

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome... PMID 34959715

  • Evidence row 306

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme a... PMID 24346263

endocannabinoid enzyme activity or metabolic mechanisms

1 research source 311 Early human research summary: preliminary human (1)

DAGL-alpha appears in rows about endocannabinoid enzyme activity or metabolic mechanisms mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 32829065

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 32829065

  • Evidence row 311

    THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: endocannabinoid enzyme act... PMID 32829065

GPR119

1 research source 968 Early human research summary: preliminary human (1)

DAGL-alpha appears in rows about GPR119 mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 30787385

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 30787385

  • Evidence row 968

    Endocannabinoids modulates GPR119; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharma... PMID 30787385

Receptor, target, metabolic, and pharmacology mechanisms

1 research source 765 Mechanistic research summary: mechanistic or pharmacological (1)

DAGL-alpha appears in rows about Receptor, target, metabolic, and pharmacology mechanisms mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 21175579

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 21175579

  • Evidence row 765

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure:... PMID 21175579

Skin and inflammatory dermatology

1 research source 711 Mechanistic research summary: mechanistic or pharmacological (1)

DAGL-alpha appears in rows studying Skin and inflammatory dermatology. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 35628241

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 35628241

  • Evidence row 711

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin,... PMID 35628241

TRP channel activity or ionotropic cannabinoid target mechanisms

1 research source 364 Mechanistic research summary: mechanistic or pharmacological (1)

DAGL-alpha appears in rows about TRP channel activity or ionotropic cannabinoid target mechanisms mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 21175579

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 21175579

  • Evidence row 364

    THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome... PMID 21175579

TRPM8

1 research source 1050 Mechanistic research summary: mechanistic or pharmacological (1)

DAGL-alpha appears in rows about TRPM8 mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 21175579

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 21175579

  • Evidence row 1050

    THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pha... PMID 21175579

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (2 row(s)), mechanistic evidence (4 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 34959715

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 32829065

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 21175579
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 35628241
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 30787385

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 34959715

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 32829065

Source-reading checklist for DAGL-alpha

  1. Open the linked PubMed or DOI record. PMID 34959715
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 24346263
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 32829065
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 21175579
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 35628241

Source Notes

DAGL-alpha source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 304

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 34959715

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review.
  2. Evidence row 306

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 24346263

    Evidence class: preclinical; Study design: Animal study. Source: Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method.
  3. Evidence row 311

    THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 32829065

    Evidence class: preliminary human. Source: Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta.
  4. Evidence row 364

    THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
  5. Evidence row 711

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 35628241

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.
  6. Evidence row 765

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
  7. Evidence row 968

    Endocannabinoids modulates GPR119; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 30787385

    Evidence class: preliminary human. Source: Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer.
  8. Evidence row 1050

    THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.